威尼托克拉克斯治疗和急性髓性白血病中新出现的耐药性机制
Gus O Nwosu1,2, David M Ross1,3,4,5, Jason A Powell6,7
1Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
Cell death & disease
|June 12, 2024
概括
威尼托克拉克斯对急性髓性白血病 (AML) 有希望,但耐药性很常见. 本综述探讨了venetoclax耐药性的机制以及在AML治疗中克服它的策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种具有攻击性的血液和骨髓癌,尽管进行密集化疗,但生存率不佳.
- 作为BH3模拟剂的Venetoclax在与标准疗法相结合时,为AML患者提供了更好的疗效和可控的毒性.
- 然而,很大一部分AML患者表现出对venetoclax的内在或获得性耐药性,导致最终复发.
研究的目的:
- 审查目前对AML中venetoclax耐药机制的理解.
- 突出最近在识别克服venetoclax耐药性的策略方面取得的进展.
主要方法:
- 关于AML中venetoclax耐药性的最近研究的文献综述.
- 分析潜在的内在和获得的耐药性的分子机制.
- 检查针对抗性途径的新型治疗策略.
主要成果:
- 对venetoclax的内在和获得性耐药性发生在大约30%的AML患者中.
- 新兴研究正在确定驱动venetoclax耐药性的关键分子途径.
- 新的治疗方法正在开发中,以使AML对venetoclax重新敏感.
结论:
- 了解venetoclax耐药机制对于改善AML治疗结果至关重要.
- 针对抗药性途径具有克服治疗失败和AML复发的巨大潜力.
- 需要对组合疗法和新药进行进一步的研究,以提高venetoclax在AML中的疗效.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
01:27Cytotoxic T Cells-mediated Immune Response
891
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
891